Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Ipamorelin

Plain-language summaryIntrigue 70 / 100

Ipamorelin is a small synthetic peptide that triggers your pituitary gland to release growth hormone, mimicking the action of ghrelin. Unlike older growth hormone releasers, it is highly selective and does not raise cortisol or prolactin, which are common stress-response side effects. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

55/100

The reference GHRP, best-in-class for selectivity, but novelty window has closed

Look, ipamorelin is basically the benchmark against which everything else in the GHRP space gets measured. That’s worth something. Raun and colleagues published the original characterization in 1998 through Novo Nordisk’s GHS program, and the key selling point has never changed: you get clean, selective GHS-R1a agonism without the coincident ACTH and prolactin stimulation that makes GHRP-2, GHRP-6, and hexarelin harder to work with when you need clean readouts on the GH axis. thats not a minor footnote. For any program trying to isolate the somatotropic effects of ghrelin-receptor activation, ipamorelin is the tool that actually lets you do that without confounding cortisol or prolactin noise.

The mechanism story is solid but not novel. The compound has been understood at the receptor level for over two decades, and the ghrelin receptor system itself is extremely well-mapped. What keeps ipamorelin interesting is the selectivity profile, not any new mechanism. You’re looking at single-receptor agonism in a mature class. The synergy with GHRH is real and useful in study design, but again, well-described. There’s nothing new in the underlying biology here, just careful pharmacology executed well.

Evidence quality is decent for a peptide in this space. Multi-lab preclinical data on GH pulsatility, IGF-1 axis effects, and bone mineral density in osteopenic rodent models. Helsinn Therapeutics advanced it into Phase 2 for postoperative ileus, and the compound performed; discontinuation was commercial, not a safety or efficacy signal. That’s worth noting. The clinical footprint is narrow and the ileus indication doesn’t map cleanly to most research use cases, so translational signal is real but context-specific.

What we like: the sourcing ecosystem for ipamorelin is more mature than almost anything else in the peptide research space. Analytical standards exist, purity characterization is tractable, and the pharmacokinetics are predictable with subcutaneous administration and a roughly 2-hour plasma half-life. If you’re running GHS-R1a studies and you dont want to argue about off-target effects, this is the right starting point.

What we don’t like: the novelty window has largely closed. This compound is nearly 30 years old, the literature is mostly confirmatory rather than exploratory at this point, and if you’re looking for the frontier of GH secretagogue research, newer selective GHS-R1a modulators are starting to appear. Ipamorelin remains the reference compound for the class, but the central questions it was built to answer have been substantially addressed. Honest verdict: it’s a workhorse, not a frontier target, and it should be scored as one.

Novelty

40

Mechanism promise

55

In-category differentiation

65

Evidence quality

55

Translational signal

52

Research bench value

68

Rationale Ipamorelin scores primarily on differentiation and bench value as the definitive clean GHS-R1a probe in a mature class; low novelty and single-receptor mechanism in a well-mapped system keep the ceiling modest despite solid multi-lab preclinical evidence and Phase 2 clinical data.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Pentapeptide growth hormone secretagogue, ghrelin receptor agonist

A 5-residue selective growth hormone secretagogue developed at Novo Nordisk in the late 1990s, characterized by GH release without coincident ACTH or prolactin stimulation.

Abstract

Ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2; CAS 170851-70-4; molecular formula C38H49N9O5; molecular weight 711.86) is a synthetic pentapeptide growth hormone secretagogue (GHS) developed at Novo Nordisk in the mid-1990s and disclosed in a 1998 paper by Raun and colleagues. Ipamorelin is a selective agonist of the growth hormone secretagogue receptor 1a (GHS-R1a, the ghrelin receptor), the receptor through which the endogenous peptide ghrelin and the small-molecule MK-0677 also act. Selective activation of GHS-R1a triggers pulsatile growth hormone (GH) release from the anterior pituitary without the concurrent stimulation of cortisol, ACTH, or prolactin that complicates the pharmacology of older GHS compounds (GHRP-2, GHRP-6, hexarelin). The selectivity profile is the basis on which Ipamorelin remains the most-cited research-grade GHS in the post-2010 literature. The compound was advanced through Phase 2 trials by Helsinn Therapeutics for postoperative ileus before development was discontinued for commercial reasons. Reported preclinical activities include dose-dependent GH pulse induction, increased IGF-1 axis activity over multi-day administration, modest effects on appetite (smaller than ghrelin’s), and accelerated bone mineral density gains in osteopenic rodent models. Plasma half-life is approximately 2 hours, with subcutaneous administration producing predictable absorption. The compound is not approved by any regulatory authority for human or veterinary use. The literature base is solid for the basic pharmacology but limited for long-term safety data in humans; the clinical record is principally from a single short-term ileus indication.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-004Open in new tab →

Download PDF →

Acquire Ipamorelin from the catalog

View Ipamorelin →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
TB-500

Plain-language summaryIntrigue 72 / 100

TB-500 is a synthetic fragment of thymosin beta-4, a protein your body makes naturally that helps tissues heal. Researchers and athletes use it for tendon, muscle, and ligament repair. Like BPC-157, it has strong animal evidence but limited human clinical data. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

48/100

Mechanistically legible tissue repair peptide with real but thin clinical signal and significant sourcing variability

Look, TB-500 sits in an awkward middle ground that its reputation rarely acknowledges. The underlying biology is real. Thymosin beta-4 is expressed at high concentration in platelets and leukocytes, and its WH2 domain motif, the LKKTETQ heptapeptide spanning residues 17 through 23, genuinely sequesters G-actin in a way that explains the downstream effects on cell migration and wound healing the preclinical literature has documented fairly consistently. That mechanistic story is one of the more legible things in the tissue repair peptide space. Multi-lab preclinical evidence covers cardiac, dermal, corneal, and tendon repair in rodent models. Thats not nothing.

The clinical translation is where things get complicated. There are two Phase 2 trials worth looking at directly: one in dry eye disease and one in pressure ulcers, both run under the RegeneRx designation RGN-352. Mixed efficacy outcomes in both. Not a catastrophe, but not the clean confirmatory signal you want before building a research program around something. Phase 3 data does not exist. The gap between the preclinical promise and the actual human readout is wider than the community tends to admit.

Theres also a sourcing problem we think is genuinely underappreciated. A non-trivial fraction of vendor preparations sold as TB-500 may be the shorter LKKTETQ heptapeptide rather than the full 43-mer acetylated Tbeta4 sequence. These are different molecules with different masses and potentially different pharmacological profiles. Without mass spectrometry confirmation on every lot, investigators are working with uncertain starting material, and that introduces noise that contaminates the interpretation of any replicated preclinical finding. The naming ambiguity is not a minor administrative footnote; its a methodological problem sitting at the center of the TB-500 literature.

What we do like: the actin-sequestration mechanism is biologically distinct from what BPC-157 is doing on the growth factor signaling side. If you are studying cell migration endpoints, angiogenic remodeling, or fibroblast behavior in a wound context, TB-500 is a genuinely useful probe rather than a pure me-too addition to the tissue repair peptide shelf. The bench value is real for that narrowly defined use case.

What we don’t like: the reputation here substantially outruns the current evidence. Novelty is low, clinical validation is incomplete and mixed, and the preparation variability problem is serious enough that results from different labs may not be directly comparable. Researchers looking for a frontier tissue repair compound would be better served engaging with the primary Tbeta4 mechanistic literature and confirming lot identity before designing any study around commercial preparations.

Novelty

40

Mechanism promise

58

In-category differentiation

42

Evidence quality

44

Translational signal

47

Research bench value

62

Rationale TB-500 has genuine mechanistic grounding via WH2-domain actin sequestration and real multi-lab preclinical replication, but two Phase 2 RCTs under RegeneRx returned mixed efficacy, and the persistent full-length vs LKKTETQ fragment ambiguity across vendor preparations actively contaminates the evidence base. Score reflects real utility with a reputation that outruns current data.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic peptide fragment of thymosin beta-4

A 43-residue acetylated synthetic peptide derived from the actin-sequestering protein thymosin beta-4, studied for tissue repair, cell migration, and angiogenic endpoints.

Abstract

TB-500 is the common research-grade designation for a synthetic acetylated peptide whose primary sequence is a fragment of human thymosin beta-4 (Tbeta4), a 43-residue actin-binding protein expressed at high concentration in platelets, leukocytes, and many other cells. The most frequently cited research-grade preparation is the full-length Tbeta4 sequence (43 amino acids; molecular weight approximately 4963 Da; CAS 77591-33-4) acetylated at the N-terminus to mimic the native post-translational modification. A small minority of vendor literature has used “TB-500” to refer to a shorter active fragment (LKKTETQ, residues 17 through 23 of Tbeta4), which is a different molecule with a different mass; investigators should confirm by mass spectrometry which sequence has been supplied. This monograph documents the full-length acetylated Tbeta4 sequence supplied as the Kodiac biolabs lot of record. Reported activities span actin sequestration, fibroblast and endothelial cell migration, angiogenic remodeling, attenuated inflammatory cytokine response, and accelerated repair of cardiac, dermal, corneal, and tendon injury models. Routes studied in the preclinical literature include intravenous, intramuscular, subcutaneous, intraperitoneal, oral, and topical administration. Plasma half-life following parenteral administration is short, on the order of one hour, but tissue retention extends substantially longer. Two Phase 2 trials of recombinant Tbeta4 in dry eye and pressure ulcer indications have been reported with mixed efficacy outcomes. The compound is not approved by any regulatory authority for human or veterinary use. The principal limitations on the strength of the published evidence are the variation in commercial preparations sold as “TB-500” and the scarcity of large independent randomized human trials.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-003Open in new tab →

Download PDF →

Acquire TB-500 from the catalog

View TB-500 →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
Selank

Plain-language summaryIntrigue 71 / 100

Selank is a synthetic seven-amino-acid peptide developed in Russia as an analog of the immune peptide tuftsin. It has anxiolytic and immunomodulating effects in research and is approved as a prescription anxiolytic in Russia. It does not produce sedation or dependence. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

42/100

Genuinely interesting neuroimmune probe from Russian development, held back by single-consortium evidence and absent Western replication

Look, Selank is one of those compounds where the backstory is genuinely interesting but the evidence base keeps you from getting too excited. Developed in the early 1990s at the Institute of Molecular Genetics in Moscow, it started as an attempt to stabilize tuftsin, a naturally occurring tetrapeptide cleaved from immunoglobulin G. Tuftsin had documented immunomodulatory effects but fell apart in plasma before doing much useful work. The Russian team appended Pro-Gly-Pro to the C-terminus, and suddenly they had a stable heptapeptide with a more complex pharmacology than the parent compound ever suggested.

The mechanism picture is what makes Selank worth knowing about. It hits GABA-A modulatory pathways, which explains the anxiolytic profile; inhibits enkephalinase, prolonging endogenous opioid peptide activity; and retains tuftsin-like immunomodulatory signaling through its core sequence. Thats three distinct biological axes in one compound, and the neuroimmune overlap is genuinely underexplored in Western labs. The idea that you can modulate anxiety phenotypes and immune tone simultaneously through a single peptide sits at an intersection that very few research tools occupy, and that gives it real probe value.

Here’s the thing, though: the evidence is almost entirely Russian-language. The compound is registered as a prescription medicine for generalized anxiety disorder in the Russian Federation, which is not nothing. It means somebody ran trials and satisfied a regulatory body. But the trials were small, sample sizes modest, and Western independent replication is essentially absent. This is the same structural problem that limits Epitalon and Cerebrolysin: single-consortium dominance, language barrier, and no serious external challenge to the methodology. We dont know whether the registration-level data would survive rigorous peer review at a major Western journal, because it hasnt been subjected to that process.

For a bench investigator working the neuroimmune axis, Selank is one of very few tools that sits specifically at the anxiety-immunity intersection. The enkephalinase inhibition angle in particular is underexplored outside Russia, and thats a legitimate open question. If your lab is studying tuftsin receptor biology, or asking how peripheral immune signals translate into CNS anxiolytic endpoints, Selank has something to offer that you cant easily replicate with a standard benzo or SSRI.

What we dont like: the evidence pyramid is inverted. Clinical registration came largely from the same group that built the compound. The Western preclinical literature is thin. Nobody has seriously challenged the most-cited findings outside the Zakusov-aligned network. Until a multi-lab Western effort produces independent data, Selank stays in the plausible-and-interesting-but-unvalidated bucket. We’d score it meaningfully higher if the Moscow consortium findings had been put under external stress and survived. They havent yet.

Novelty

38

Mechanism promise

50

In-category differentiation

40

Evidence quality

35

Translational signal

42

Research bench value

45

Rationale Selank’s multi-mechanism profile (GABA-A modulation, enkephalinase inhibition, tuftsin-like immunomodulation) is legitimately interesting and earns it above-floor scores on mechanism and bench value, but the evidence base is structurally compromised by near-total reliance on the same Moscow consortium that developed the compound, with minimal Western replication. Russian prescription registration is meaningful but insufficient to move the evidence axis much; this places Selank squarely in single-lab-only territory alongside Epitalon and Cerebrolysin.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic heptapeptide anxiolytic, tuftsin analog

A 7-residue peptide developed at the Russian Academy of Sciences as a stable analog of tuftsin, characterized for anxiolytic, immunomodulatory, and cognitive endpoints in a substantial Russian-language literature.

Abstract

Selank (sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro; CAS 129954-34-3; molecular formula C33H57N11O9; molecular weight 751.85) is a synthetic heptapeptide developed in the early 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the Zakusov Research Institute of Pharmacology. The peptide is a stabilized analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from immunoglobulin G that has documented immunomodulatory effects but a very short half-life. Selank extends the tuftsin sequence with the C-terminal tripeptide Pro-Gly-Pro to confer protection against rapid peptidase degradation. The compound has been studied principally in the Russian clinical and preclinical literature, with the largest body of work on anxiolytic effects in generalized anxiety disorder, immunomodulatory effects in viral and bacterial infection models, and cognitive effects in attention and memory tasks. Selank is registered as a prescription medicine in the Russian Federation for the treatment of generalized anxiety disorder under the trade name Selank Bioregulator. The compound is not approved by any regulatory authority outside the Russian Federation; clinical use in the United States, the European Union, and Japan is off-label and outside the scope of regulatory oversight. The principal limitations on the strength of the evidence are the dominance of the Russian-language literature, limited Western independent replication of the most-cited findings, and the relatively small clinical sample sizes in the published trials.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-010Open in new tab →

Download PDF →

Acquire Selank from the catalog

View Selank →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
GHK-Cu

Plain-language summaryIntrigue 68 / 100

GHK-Cu is a tiny three-amino-acid peptide bound to copper. It is naturally present in human plasma at decreasing levels with age. Research suggests it supports skin healing, hair growth, and tissue regeneration. It is widely used in cosmetic skincare. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

52/100

Reference copper transport peptide with real cosmetic track record but modest novelty and unresolved mechanistic breadth

Look, GHK-Cu has been around since 1973. Pickart isolated it from human plasma as a grad student at UCSF, and in the five decades since it has accumulated what is probably the most multidisciplinary literature base of any small bioactive peptide in serious research circulation. That breadth is real. It’s also part of the problem.

The core mechanism involves copper(II) coordination through the His imidazole nitrogen, the Gly N-terminus, and the Lys side chain, forming a stable picomolar-affinity complex that functions as a copper chaperone at the tissue level. That part is well-characterized. Where it gets complicated is the downstream biology: multiple groups have reported modulation of upward of 4,000 human genes in cultured cells, effects on collagen and elastin synthesis, anti-inflammatory cytokine shifts, hair follicle cycling, and antioxidant pathway induction. We think the copper transport story is the load-bearing mechanism; the gene expression data is interesting but the causal chain linking copper delivery to that breadth of transcriptional change isnt fully worked out. The monograph flags this honestly: effects at one dose or route don’t always translate to another context, and that’s a real limitation on how seriously you can stack the preclinical literature.

Translational signal is strongest in the dermal space. GHK-Cu has genuine cosmetic regulatory approval in multiple jurisdictions as Copper Tripeptide-1, which gives it a legitimate bench-to-market arrow that most research peptides lack entirely. For wound healing and dermal remodeling, the human-relevant signal is real, even if the clinical trial infrastructure is thin by pharma standards. Systemic use is a different story: there’s no FDA IND, the pharmacokinetic data for non-topical routes is heterogeneous, and programs working systemically are largely building on preclinical foundations that weren’t designed for that purpose.

What we like here is the bench utility. If your program involves copper biology, wound repair, or skin extracellular matrix remodeling, GHK-Cu is the reference compound. Thats not a small thing. The age-related decline in plasma GHK-Cu concentrations is a legitimate gerontological question, and the compound is a real probe for investigating those dynamics. The analytical challenge is stoichiometry: vendors don’t always specify which GHK:Cu(II) complex they’re supplying, and the 1:1 complex behaves differently from the 2:1 and 1:2 forms. Sourcing verification matters more here than for most peptides in this class.

Honestly, the novelty story is what it is: this isn’t a frontier compound. The gene expression angle and the longevity hypothesis keep it from being purely historical, but we’re not going to pretend it scores on freshness. What GHK-Cu offers is a well-characterized, multidisciplinary research tool with a real cosmetic regulatory track record and a manageable sourcing landscape, for programs where copper-peptide biology is actually the question being asked.

Novelty

40

Mechanism promise

52

In-category differentiation

58

Evidence quality

55

Translational signal

52

Research bench value

62

Rationale GHK-Cu earns its score through genuine bench utility as the field’s reference copper transport peptide and a real translational signal in dermal applications, offset by modest novelty (discovered 1973), heterogeneous preclinical evidence across dose and route, and a causal chain linking copper delivery to 4,000-plus gene modulation that remains incompletely characterized.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tripeptide-copper(II) complex, copper transport peptide

A naturally occurring tripeptide that binds copper(II) with very high affinity, characterized as a wound healing and tissue remodeling peptide with a substantial multidisciplinary literature.

Abstract

GHK-Cu (sequence Gly-His-Lys complexed with Cu(II); CAS 89030-95-5; molecular formula C14H22N6O4Cu; molecular weight 401.91) is a naturally occurring tripeptide-copper(II) complex first isolated from human plasma in 1973 by Loren Pickart, then a graduate student at the University of California San Francisco. The free tripeptide GHK is present in human plasma at low micromolar concentrations and has very high affinity for Cu(II) (apparent dissociation constant in the picomolar range), forming the GHK-Cu complex that is the active species in many of the published bioassays. The compound has the most multidisciplinary published literature of any of the small bioactive peptides in research-grade circulation, with documented or suggested effects on wound healing, hair follicle activity, dermal collagen and elastin synthesis, anti-inflammatory cytokine modulation, modulation of more than 4,000 human genes (in cultured cells), and antioxidant defense. Plasma GHK-Cu concentrations decline with age, which is the rationale for many of the gerontology-focused claims. GHK is approved as a topical cosmetic ingredient in many jurisdictions and is widely used in dermatologic preparations. There is no FDA-approved IND for systemic GHK-Cu in any indication. The principal limitations on the strength of the evidence are heterogeneity in the dose, route, and formulation of GHK-Cu across the published preclinical literature; effects observed at one dose or route do not always translate to other contexts.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-007Open in new tab →

Download PDF →

Acquire GHK-Cu from the catalog

View GHK-Cu →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
Semax

Plain-language summaryIntrigue 73 / 100

Semax is a synthetic seven-amino-acid peptide derived from a fragment of ACTH (a stress hormone). It is approved in Russia as a nootropic and stroke recovery medication. Research suggests effects on BDNF, dopamine, and other neurotrophic systems. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

42/100

Multi-mechanistic neuropeptide with a genuine mechanism story undermined by a Russian-only evidence base

Look, Semax is one of those compounds where the mechanism story is genuinely more interesting than the evidence base deserves. The Institute of Molecular Genetics built out a real mechanistic rationale over decades: ACTH(4-10) fragment, Pro-Gly-Pro tail to buy it some peptidase protection, a multi-target profile that touches melanocortin receptors, upregulates BDNF and NGF expression, and inhibits enkephalinase. Thats a substantive mechanism, and its not a boring one. Most synthetic nootropic peptides in this class operate on a single receptor or a loosely defined neuroprotection claim. Semax at least has specific, testable downstream biology.

The problem is the literature. Almost everything worth citing comes out of Russian groups, often the same consortium that developed the compound. Western labs have not meaningfully picked up the replication work. The clinical registration in the Russian Federation for ischemic stroke recovery and TIA is meaningful in the sense that someone ran studies and got a regulatory nod, but those studies don’t meet the bar Western reviewers would require: small sample sizes, limited methodological transparency in the published reports, no independent multi-site replication. Its the Cerebrolysin problem repeated: decades of regional literature, real signal, but the epistemic infrastructure that would let a Western investigator trust the effect size simply isn’t there.

What we like about Semax is the BDNF and NGF upregulation angle. As interest in neuroplasticity and neurotrophic factor biology has accelerated in Western research, the documented effects on BDNF expression in rodent ischemia models and cognitive paradigms give it a hook worth taking seriously. The melanocortin receptor pharmacology is also underexplored in the West, and Semax is one of the cleaner available probes for that system without engaging the steroidogenic machinery of full ACTH. If youre building a comparative peptide panel for neuroplasticity work, Semax belongs in the conversation.

We dont think Semax is a bad compound. We think its a compound that Western investigators have simply not touched at scale, and that gap is both a limitation and an opportunity. Lot 20260331 comes in at 99.75 percent HPLC purity, which is solid, and the corrected molecular weight of 813.92 is consistent with the reference literature. Reconstitution and handling are straightforward for a heptapeptide of this profile.

What keeps the score at 42 is straightforward: evidence quality is not replication-grade by Western standards, differentiation within the cognitive peptide space is real but not dominant, and the translational signal is essentially conditional on trusting a regional regulatory record. Semax sits in the tier of compounds that are worth including in a research library and worth using as a tool, but not worth anchoring a program around until someone runs serious independent replication outside the originating consortium.

Novelty

40

Mechanism promise

55

In-category differentiation

38

Evidence quality

35

Translational signal

40

Research bench value

45

Rationale Semax scores well on mechanism diversity, touching melanocortin receptors, upregulating BDNF and NGF, and inhibiting enkephalinase, but the evidence base is dominated by a single regional literature with no meaningful Western replication, placing it alongside Cerebrolysin as a compound with real preclinical signal and deeply uncertain epistemic standing for a Western research program. The clinical registration in Russia is meaningful but doesn’t substitute for independent multi-site trials at Western standards.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic heptapeptide nootropic, ACTH(4-10) analog

A 7-residue peptide derived from ACTH(4-10), developed at the Russian Academy of Sciences and registered for clinical use in stroke recovery and cognitive indications.

Abstract

Semax (sequence Met-Glu-His-Phe-Pro-Gly-Pro; CAS 80714-61-0; molecular formula C37H51N9O10S; molecular weight 813.92) is a synthetic heptapeptide developed in the early 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences. The peptide is a stabilized analog of the N-terminal heptapeptide of adrenocorticotropic hormone (ACTH(4-10)), a fragment that retains many of the cognitive and neuroprotective effects of the parent hormone without the steroidogenic effects mediated by the C-terminal portion. Semax extends the ACTH(4-10) sequence with the C-terminal tripeptide Pro-Gly-Pro (the same stabilizing extension used in Selank) to confer protection against rapid peptidase degradation. The compound is registered as a prescription medicine in the Russian Federation for ischemic stroke recovery, transient ischemic attack, and several other neurological and cognitive indications. The published preclinical and clinical record includes work on neuroprotection in cerebral ischemia models, modulation of BDNF and NGF expression, melanocortin receptor signaling effects, and cognitive enhancement endpoints. The compound is not approved by any regulatory authority outside the Russian Federation. The principal limitations on the strength of the evidence are the dominance of the Russian-language literature, limited Western independent replication of the most-cited findings, and the relatively small clinical sample sizes by Western regulatory standards. The lot of record at Kodiac biolabs (lot 20260331) carries a vendor-reported HPLC purity of 99.75 percent.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-011Open in new tab →

Download PDF →

Acquire Semax from the catalog

View Semax →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
9-Me-BC

Plain-language summaryIntrigue 64 / 100

9-Me-BC (9-methyl-beta-carboline) is a small molecule based on the beta-carboline scaffold. Research suggests it has dopaminergic neuroprotective effects, with potential implications in Parkinson disease research. Capsule format here. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

44/100

Genuine dopaminergic neuroprotective signal, but single-consortium evidence and zero human data cap the research priority

Look, the mechanism story here is genuinely worth reading. 9-Me-BC sits inside the beta-carboline family but the 9-position methylation does something important: it substantially reduces MAO-A affinity relative to harmine or harmaline and strips away most of the psychoactive profile those relatives carry. What you get instead is a compound characterized for dopaminergic neuroprotective effects, increased dopamine neuron differentiation in cell culture, and elevated BDNF expression in rodent brain tissue. For anyone running experiments on dopaminergic system maintenance or neurotrophic factor dynamics, that combination is a real signal worth paying attention to.

The differentiation angle matters for experimental design. If youre trying to probe dopaminergic neuroprotection without MAO-A pharmacology confounding your readout, 9-Me-BC carves out a reasonably clean space. The 182 Da molecular weight and reported oral bioavailability make it easier to work with than peptide-based approaches to adjacent questions. The BDNF connection adds a second axis that could be useful for designs crossing dopaminergic and neurotrophic factor biology.

Here’s the thing though: when you actually audit where the evidence comes from, the limitations are serious. The research record dates to the 2010s and is dominated by a small cluster of German neuroscience labs. Thats not a fatal problem on its own, but there is no independent multi-lab replication that would let you trust the effect sizes, and there is no human clinical data at all. Not preliminary phase 1 work, not small-N observational, nothing. So you have an interesting mechanism and rodent plus cell culture data from a single research community, and the translational arrow is pointing at a question mark.

We’ve seen this pattern before. The BPC-157 literature has the same structural problem, and the credibility of that body of work has aged in ways that should make any serious investigator cautious about single-consortium signals. 9-Me-BC isn’t in worse shape than BPC-157, but it isn’t clearly in better shape either, and the research record is shorter.

Honestly, this is a compound worth monitoring. If independent labs begin replicating the dopaminergic differentiation findings, the score changes. Right now, the mechanism promise earned it a real look; the evidence base hasn’t earned priority placement in an active research program. Worth knowing about. Not worth leading with.

Novelty

62

Mechanism promise

57

In-category differentiation

44

Evidence quality

22

Translational signal

18

Research bench value

50

Rationale The 9-position methylation creates a meaningfully distinct pharmacological profile from classic psychoactive beta-carbolines, with real dopaminergic neuroprotection and BDNF signal in rodent work. However, the published record is dominated by a tight cluster of German labs with no independent multi-lab replication and no human clinical data of any kind, pulling evidence and translational scores to the floor.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Beta-carboline alkaloid, dopaminergic neuroprotective small molecule (capsule format)

A 182 Da methylated beta-carboline alkaloid characterized for dopaminergic neuroprotective effects, increased dopamine neuron differentiation, and BDNF expression in animal models. Supplied as 30 capsules x 20 mg.

Abstract

9-Methyl-beta-carboline (9-Me-BC; CAS 2521-07-5; molecular formula C12H10N2; molecular weight 182.22) is a small-molecule beta-carboline alkaloid bearing a methyl substituent on the 9-position indole nitrogen. The compound is a member of the broader beta-carboline family, naturally occurring alkaloids found in trace concentrations in many plants (notably the harmal family of psychoactive plants used in traditional preparations) and present at low concentrations in mammalian tissues including human plasma. The synthetic 9-methylated variant has attracted research interest beginning in the 2010s for a distinctive pharmacological profile that combines dopaminergic neuroprotective effects, increased dopamine neuron differentiation in cell culture, and elevated BDNF expression in rodent brain. Unlike many psychoactive beta-carbolines (harmaline, harmine, others), 9-Me-BC has substantially reduced affinity for the monoamine oxidase A enzyme and substantially reduced psychoactive effects at the doses used in published preclinical work. The compound is supplied at Kodiac biolabs as a 30-capsule oral preparation, 20 milligrams per capsule, reflecting the small molecule’s stability and good oral bioavailability. There is no FDA-approved IND for 9-Me-BC in any indication. The principal limitations on the strength of the evidence are the relatively short duration of the published research record, dominance of a small number of laboratories (primarily in the German neuroscience research community), and the absence of human clinical data.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-015Open in new tab →

Download PDF →

Acquire 9-Me-BC from the catalog

View 9-Me-BC →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
SS-31

Plain-language summaryIntrigue 88 / 100

SS-31, also called elamipretide, is a four-amino-acid peptide that selectively targets the inner mitochondrial membrane. It binds cardiolipin (a unique mitochondrial lipid) and stabilizes the mitochondrial membrane during stress, with research interest in heart failure, kidney disease, and aging. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

63/100

Cardiolipin-targeted mitochondrial probe with real Phase 2/3 clinical data, mixed outcomes, and strong bench utility in mitochondrial disease models

Look, SS-31 is one of those compounds where the mechanism is genuinely beautiful and the clinical story is genuinely complicated. Hazel Szeto’s group at Cornell spent years establishing that cardiolipin, the signature phospholipid of the inner mitochondrial membrane, is a target you can actually modulate with a synthetic tetrapeptide. That insight wasn’t obvious when the SS series was first described. The Dmt substitution over tyrosine in SS-02 wasn’t cosmetic either: it’s what gives SS-31 the stability and binding affinity that makes it useful at all in biological systems, and mass spec distinguishes the two readily enough that adulteration is a tractable quality concern rather than an invisible one.

The mechanistic story is compelling at the bench level. Cardiolipin doesn’t just sit there in the inner membrane looking pretty; it scaffolds the supercomplexes of the electron transport chain, particularly the Complex I/III/IV associations. When you perturb that environment through oxidative stress, the supercomplexes destabilize, electron flow becomes leaky, ROS output increases, and you get the downstream cascade that defines mitochondrial dysfunction in aging and ischemic disease. SS-31 interrupts that cascade upstream, at the lipid level, rather than scavenging ROS after the fact. Thats mechanistically more interesting than antioxidant supplementation and it explains why the compound has stayed in serious investigator hands even as its clinical arc has been uneven.

The clinical translation is where the story gets messier. Stealth BioTherapeutics ran a genuine program: Phase 2 work in cardiac ischemia, heart failure with preserved ejection fraction, Barth syndrome, primary mitochondrial myopathies, and age-related macular degeneration. The AMD program hit a real wall; the FDA issued a complete response letter for geographic atrophy requesting additional data, and that’s a setback that can’t be soft-pedaled. But the Barth syndrome and primary mitochondrial myopathy results are legitimately interesting. Barth is a rare cardiolipin remodeling disorder where elamipretide’s mechanism isn’t just plausible, its almost mechanistically required. Phase 2 functional improvements in that population were meaningful. Primary mitochondrial myopathy data has been more modest but directionally real.

What we like: SS-31 remains a useful probe for cardiolipin biology at the bench. If you’re running oxidative stress models, aging models, or ischemia-reperfusion work, having SS-31 as a chemical tool lets you ask specifically whether cardiolipin stabilization is part of whatever protective phenotype you’re seeing. Thats real probe value that doesn’t depend on the clinical outcomes resolving cleanly.

What we don’t like: this peptide has been around since the early 2000s, the core mechanism literature is mature, and the Phase 3 record is mixed at best. SS-31 isn’t breaking new ground anymore; it’s validating or failing to validate an established idea in new disease contexts. For an investigator building a new research program from scratch, SS-31 is a well-characterized tool in an active space, not a frontier target. Solid mid-tier compound, genuinely important in its niche, not the first thing we’d prioritize for an undirected lab.

Novelty

55

Mechanism promise

72

In-category differentiation

65

Evidence quality

60

Translational signal

57

Research bench value

68

Rationale SS-31 earns its mid-tier placement on genuine mechanistic elegance (cardiolipin supercomplex stabilization upstream of ROS) and a real multi-indication clinical program through Stealth BioTherapeutics, but the compound’s 20-year vintage, an FDA complete response letter for geographic atrophy, and mixed Phase 3 signals pull novelty and translational scores down; bench value stays solid because it remains the reference peptide probe for cardiolipin biology and has no real structural analogue for that specific question.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic tetrapeptide mitochondrial-targeting cardiolipin-binding peptide

A 4-amino-acid mitochondrial-targeting peptide developed at Cornell University, characterized for binding to cardiolipin in the inner mitochondrial membrane and protecting mitochondrial function in oxidative stress.

Abstract

SS-31 (sequence D-Arg-Dmt-Lys-Phe-NH2, also known as elamipretide, Bendavia, MTP-131; CAS 736992-21-5; molecular formula C32H49N9O5; molecular weight 639.79) is a synthetic tetrapeptide developed in the laboratory of Hazel Szeto at Cornell University Medical College beginning in the early 2000s. The peptide is the most extensively characterized member of the Szeto-Schiller (SS) series of mitochondrial-targeting tetrapeptides. The biological mechanism is binding to cardiolipin in the inner mitochondrial membrane, which protects the membrane lipid environment from peroxidation, stabilizes the supercomplexes of the electron transport chain, and improves mitochondrial efficiency in conditions of oxidative stress or mitochondrial dysfunction. The compound is the active pharmaceutical ingredient in elamipretide (Bendavia), which has been advanced through Phase 2 and Phase 3 clinical trials by Stealth BioTherapeutics for primary mitochondrial myopathies, age-related macular degeneration (dry AMD with geographic atrophy), Barth syndrome, and other mitochondrial dysfunction indications. The clinical record is mixed; the most-promising results have come in Barth syndrome and primary mitochondrial myopathy. The compound is not approved by any regulatory authority for human or veterinary use as of this revision; recent FDA review in geographic atrophy resulted in a complete response letter requesting additional data. The Kodiac biolabs lot of record is SW260307, manufactured 7 March 2026 by Xian Sowu Biotech, with a vendor COA assay of 99.62 percent and a supplementary HPLC area-percent of 99.18 percent at 220 nm; both documents are archived on the lab results page.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-012Open in new tab →

Download PDF →

Acquire SS-31 from the catalog

View SS-31 →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
Dihexa

Plain-language summaryIntrigue 87 / 100

Dihexa is a small molecule based on a fragment of angiotensin (a blood pressure hormone). Despite that origin, what makes it interesting is what it does in the brain: research shows it dramatically increases the formation of new connections between brain cells (synapses), with potential applications in Alzheimer disease and cognitive enhancement. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundContested mechanism

52/100

Novel AT4 peptidomimetic with gutted evidence base after 2025 JPET retractions and failed clinical program

Look, the Dihexa story is one of the more spectacular collapses in recent CNS research, and it’s worth understanding what actually happened before deciding whether the compound has any remaining bench value.

The foundational papers, four JPET publications from the Harding lab at WSU between 2011 and 2014, were retracted in April 2025 following confirmed Western blot manipulation: band splicing and duplication across distinct experimental conditions. Those papers underwrote Athira Pharma, a $204 million IPO, and the clinical program that followed. The clinical lead, fosgonimeton (ATH-1017), failed to meet primary endpoints in both the LIFT-AD Phase 2/3 trial in mild-to-moderate Alzheimer disease and the SHAPE Phase 2 trial in dementia with Lewy bodies. A DOJ False Claims Act settlement landed in January 2025 for $4.07 million. The HGF/c-Met mechanism hypothesis that powered all of this is now scientifically untenable in its original form.

So what’s left? Honestly, more than nothing. Behavioral data from Morris water maze and novel object recognition paradigms that doesn’t depend on Western blot immunochemistry hasn’t been retracted. Electrophysiology work showing LTP facilitation in hippocampal slice preparations remains in the record. Synaptogenesis data from microscopy-based assays is similarly intact. These arent nothing: they suggest the compound does something pharmacologically active in the CNS, even if the original mechanistic story is gone.

The AT4 receptor / IRAP (insulin-regulated aminopeptidase) angle is the current best hypothesis for what Dihexa is actually doing. AT4-class pharmacology is genuinely understudied, and Dihexa’s profile as a small, orally active, BBB-penetrant peptidomimetic with picomolar activity in behavioral models is still unusual chemistry. There aren’t many compounds with those combined properties in this space, retracted mechanism or not. As an N-hexanoic-Tyr-Ile analog, it sits in a chemical class that has essentially no other well-characterized members at the CNS level.

We think the appropriate posture for bench investigators is to treat the HGF/c-Met story as dead, skip the Western blot replication attempts, and focus instead on what the compound does in electrophysiology and behavioral models relative to other AT4-class probes. The novelty and differentiation scores here are real: unusual chemistry, no close competitors in its niche. The evidence and translational scores are gutted because the clinical program failed and the core mechanistic papers are gone. That’s what a 52 looks like for a compound: genuinely interesting bench chemistry wrapped in a thoroughly compromised evidentiary record. Source it carefully, verify by HPLC, and treat the retracted literature as background context rather than foundation.

Novelty

70

Mechanism promise

50

In-category differentiation

70

Evidence quality

28

Translational signal

25

Research bench value

58

Rationale High novelty and differentiation scores survive intact because the compound’s AT4-derived peptidomimetic chemistry is genuinely unusual and uncontested; evidence and translational axes are severely depressed by the April 2025 JPET retractions of all four foundational HGF/c-Met papers and the failed fosgonimeton Phase 2/3 program, consistent with the spec’s explicit Dihexa callout targeting overall 52-58.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Angiotensin IV analog (procognitive small peptidomimetic)

A small angiotensin IV analog with a contested mechanism of action, a high-profile commercialization failure, and a literature record selectively retracted in 2025.

Abstract

Dihexa, also known as PNB-0408 and N-hexanoic-Tyr-Ile-(6) amino-hexanoic amide, is a hexapeptide-derived small molecule developed in the Harding laboratory at Washington State University as a procognitive analog of angiotensin IV. It was foundationally hypothesized to act through agonism of the hepatocyte growth factor (HGF) / c-Met receptor system, a mechanism that promised oral bioavailability, blood-brain barrier penetration at picomolar potency, and rapid synaptogenesis in cortical and hippocampal neurons. Between 2011 and 2014, four peer-reviewed publications established the compound’s commercial pipeline and underwrote the formation of Athira Pharma, a publicly traded biotechnology firm that raised over 204 million dollars in a 2020 initial public offering. Each of these four publications was retracted by the Journal of Pharmacology and Experimental Therapeutics in April 2025 following findings of academic misconduct, specifically the splicing and duplication of Western blot bands across distinct experimental conditions. The Department of Justice settled a False Claims Act qui tam action against Athira Pharma in January 2025 for 4.07 million dollars. The clinical lead derived from this program, fosgonimeton (ATH-1017, NDX-1017), failed to meet primary endpoints in the LIFT-AD Phase 2/3 trial in mild-to-moderate Alzheimer disease and the SHAPE Phase 2 trial in dementia with Lewy bodies. This monograph reviews what is now established about Dihexa’s chemistry, pharmacokinetics, behavioral effects, and clinical record, separating the verified record from the retracted, and provides sourcing, identity verification, reconstitution, and handling guidance for in vitro and in vivo investigative work.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-001Open in new tab →

Download PDF →

Acquire Dihexa from the catalog

View Dihexa →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
5-Amino-1MQ

Plain-language summaryIntrigue 72 / 100

5-Amino-1MQ is a small molecule that selectively inhibits the NNMT enzyme. NNMT degrades NAD+ precursors and methyl donors; inhibiting it boosts cellular energy and fat metabolism, with research interest in obesity and metabolic disease. Capsule format here. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

59/100

Novel NNMT inhibitor with elegant dual-node mechanism and solid preclinical case, human evidence still absent

Yeah, 5-Amino-1MQ is one of the more interesting small molecules to come out of academic medicinal chemistry in the last decade. The target, nicotinamide N-methyltransferase, had been a curiosity in cancer biology for years before anyone asked whether selective inhibition might be pharmacologically useful outside the oncology context. What changed is a pair of mechanistic insights that make NNMT genuinely interesting for metabolic and aging research: the enzyme simultaneously drains nicotinamide away from the NAD+ salvage pathway and consumes SAM, the universal methyl donor. Block NNMT and you potentially shift both the cellular NAD+ pool and methylation potential in the same direction. Thats the kind of elegant dual-node mechanism that gets bench scientists interested, and it’s distinct enough from standard NAD+ precursor supplementation to justify its own research program.

The evidence base is real but you have to be honest about what it consists of. Most of it is academic rodent work, primarily adipose and skeletal muscle stem cell models. The obesity model data from the Jacobson group and related labs is reasonably well-replicated at the preclinical level, with consistent effects on body composition, adipocyte size, and metabolic markers in diet-induced obesity models. The skeletal muscle stem cell aging angle is genuinely interesting and addresses a different biology than the adipose story. The trouble is there’s essentially no human data. No IND, no phase 1 safety signal to anchor on, no pharmacokinetic data in people to confirm that the rodent predictions hold under the real constraints of human metabolism.

What we like here is that 5-Amino-1MQ is the reference compound for NNMT biology full stop. If you’re studying this target in cancer, adipose, or aging contexts, this is the tool you reach for. There isn’t a cleaner or better-characterized selective inhibitor available for in vitro or in vivo work, which gives it real bench utility that extends beyond its own pharmacological story into any program touching NAD+ biology or one-carbon metabolism.

What we dont like is the evidence maturity problem. The research record is short, the human signal is absent, and there’s a real open question about how well the rodent adipose phenotype translates. The SAM depletion axis hasn’t been fully characterized for off-target methylation effects under prolonged dosing, and that gap matters when you’re talking about a compound that touches the universal methyl donor. Until there’s more replication across independent labs and some pharmacokinetic anchoring in humans, this stays in the promising preclinical bucket.

The score lands at 59 because the target and mechanism are genuinely novel, the preclinical case is credible, and the bench utility is real, but the translational gap is wide enough that you cant call it more than that. For investigators studying NAD+ biology, adipose metabolism, or muscle stem cell aging, 5-Amino-1MQ is probably already on your list. For everyone else, worth knowing about but premature to center a research program around.

Novelty

68

Mechanism promise

72

In-category differentiation

68

Evidence quality

38

Translational signal

38

Research bench value

60

Rationale Scores well on novelty and mechanism because NNMT inhibition with dual NAD+/SAM connectivity is a genuinely recent and elegant target, and 5-Amino-1MQ is the field reference compound; evidence quality and translational signal are pulled down significantly by the short research record and total absence of human pharmacokinetic or efficacy data.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Small-molecule selective NNMT inhibitor (capsule format)

A 159 Da quinolinium small molecule that selectively inhibits nicotinamide N-methyltransferase, characterized for effects on adipose metabolism and skeletal muscle stem cell function. Supplied as 60 capsules x 50 mg.

Abstract

5-Amino-1-methylquinolinium iodide (5-Amino-1MQ; CAS 954126-98-8; molecular formula C11H12N2; molecular weight 159.20 for the cation; the iodide salt has additional mass) is a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT, EC 2.1.1.1), the enzyme that methylates nicotinamide to N1-methylnicotinamide using S-adenosylmethionine (SAM) as the methyl donor. NNMT activity diverts nicotinamide away from the NAD+ salvage pathway and consumes SAM, which connects NNMT activity to both the cellular NAD+ pool and the methylation potential of the cell. NNMT is overexpressed in many cancers (where it has been characterized as an “oncometabolic” enzyme) and in obesity-associated white adipose tissue, where it has been linked to insulin resistance and to the metabolic dysfunction phenotype. Selective NNMT inhibitors including 5-Amino-1MQ have been developed primarily by academic medicinal chemistry groups beginning in the late 2010s and have been characterized in cell culture, in vivo rodent obesity and aging models, and in skeletal muscle stem cell and aging models. The compound is supplied at Kodiac biolabs as a 60-capsule oral preparation, 50 milligrams per capsule, reflecting the small molecule’s stability and oral bioavailability. There is no FDA-approved IND for 5-Amino-1MQ in any indication. The compound is not a regulated drug substance in the United States, the European Union, or Japan. The principal limitations on the strength of the evidence are the relatively short duration of the published research record and the limited human safety and efficacy data.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-014Open in new tab →

Download PDF →

Acquire 5-Amino-1MQ from the catalog

View 5-Amino-1MQ →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
NAD+

Plain-language summaryIntrigue 70 / 100

NAD+ (nicotinamide adenine dinucleotide) is a cofactor every cell uses for energy production and signaling. NAD+ levels decline with age, driving research interest in supplementation as an anti-aging strategy. Available as injection or supplement. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

38/100

Foundational cellular cofactor with real aging biology, but precursors dominate the research frontier

Cap applied Foundational metabolite cap (max 38)

Look, NAD+ is perhaps the most important small molecule in cellular biology that you’d never call a novel research compound. It’s been known since Arthur Harden’s 1906 Nobel-adjacent work on yeast fermentation, and its three-way role as redox carrier, sirtuin substrate, and PARP feedstock has been textbook material for decades. Scoring a foundational cellular metabolite on research novelty is an odd exercise, but thats exactly what we’re doing, and the answer is honest: NAD+ the molecule doesn’t score well because we already understand it.

The supplementation angle is where things get more interesting, and it’s the reason NAD+ deserves more than a vitamins-and-minerals dismissal. Starting with the Guarente and Sinclair groups’ sirtuin work in the early 2010s, and accelerating through the Imai lab’s 2013 demonstration of age-related NAD+ decline in mice, a serious research community has built up around the depletion-with-aging hypothesis. The biology is real: NAD+ declines substantially in older mammals, SIRT1/SIRT3 activity tracks it, PARP activity rises with DNA damage and competes for the same pool, and CD38 upregulation in aging tissue may be a primary driver of the decline. That’s genuinely interesting territory.

Here’s the problem for this particular product: the direct oxidized free acid is almost never the molecule a serious investigator wants to work with for supplementation research. Poor oral bioavailability means precursors, specifically nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), do essentially everything NAD+ supplementation research needs, more efficiently and with cleaner dose-response curves in animal models. The precursors have the clinical trial basis; they have the Elysium and ChromaDex datasets; they have the longitudinal aging studies. Direct NAD+ infusion has been studied and the acute bioenergetic effects are real, but the programs that matter run on precursors.

What keeps this from scoring lower is bench utility. If you’re running sirtuin deacetylase assays, PARP activity assays, or CD38 kinetics, you need direct NAD+ as a substrate reference. It’s an essential reagent for characterizing the very enzyme systems that make the aging-NAD+ story interesting. That’s real value and we’d never argue otherwise.

As a research compound in the sense this library is built around, NAD+ is foundational background rather than frontier. The investigators doing the interesting work use it as a tool to study the pathways that deplete it, not as the experimental variable. If you’re chasing the sirtuin biology or the CD38 angle, look at precursors and CD38 inhibitors like apigenin or 78c. NAD+ is where the arrows point, not where the interesting questions live.

Novelty

25

Mechanism promise

48

In-category differentiation

30

Evidence quality

60

Translational signal

42

Research bench value

62

Rationale NAD+ is a century-old cofactor with genuine aging-research relevance, but the direct oxidized free acid form is outcompeted by NMN and NR precursors for supplementation research; bench utility as a substrate reference for sirtuin, PARP, and CD38 assays keeps it from bottoming out, but novelty and differentiation anchor the score well below where the aging biology alone might suggest.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Pyridine nucleotide cofactor, redox carrier and substrate for sirtuins, PARPs, and CD38

An obligate intracellular dinucleotide cofactor essential for hundreds of enzymatic reactions, supplied for research use as the oxidized free acid form for parenteral or topical research.

Abstract

Nicotinamide adenine dinucleotide (NAD+; CAS 53-84-9; molecular formula C21H27N7O14P2; molecular weight 663.43) is a small-molecule pyridine dinucleotide cofactor that functions in three biologically distinct roles: as the dominant cellular electron-transfer cofactor in oxidative metabolism (where it cycles between the oxidized NAD+ and reduced NADH forms), as the substrate for the sirtuin family of NAD+-dependent deacetylases (which hydrolyze NAD+ to nicotinamide and ADP-ribose), and as the substrate for poly-ADP-ribose polymerases (PARPs) and the CD38 ecto-enzyme (both of which also consume NAD+). Cellular NAD+ concentrations are tightly regulated and decline substantially with age in humans and other mammals; the age-related decline correlates with reduced sirtuin activity, impaired DNA damage repair, and a constellation of metabolic dysfunctions that has motivated substantial research interest in NAD+ supplementation as a geroprotective intervention. The research-grade product supplied as “NAD+” is the oxidized free acid form, which has poor oral bioavailability but is suitable for parenteral administration in research models. Better-characterized parenteral approaches use NAD+ precursors (nicotinamide riboside NR and nicotinamide mononucleotide NMN), which are more efficiently absorbed orally and converted intracellularly to NAD+. Direct NAD+ administration in research-grade dosing has been used in study of cellular bioenergetics, neurological function, and metabolic endpoints. The compound is not approved by any regulatory authority for human or veterinary use as a therapeutic; NAD+ is also widely available as a food supplement under separate regulatory frameworks.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-013Open in new tab →

Download PDF →

Acquire NAD+ from the catalog

View NAD+ →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026

←Previous Page

1 … 66 67 68 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.